A phase 2b, randomized, double-blind, placebo-controlled, clinical trial of atacicept for treatment of IgA nephropathy

Atacicept is a first-in-class, dual anti-B-cell Activation Factor–A Proliferation-Inducing Ligand fusion protein in clinical evaluation for treatment of IgA nephropathy. To compare efficacy and safety of atacicept versus placebo in patients with IgAN, this randomized, double-blind, placebo-controlled phase 2b clinical trial ORIGIN enrolled 116 individuals with biopsy-proven IgA nephropathy. Participants were randomized to atacicept 150, 75, or 25 mg versus placebo once weekly for up to 36 weeks. Primary and key secondary endpoints were changes in urine protein creatinine ratio based on 24-hour urine collection at weeks 24 and 36, respectively, in the combined atacicept 150 mg and 75 mg group versus placebo.…

• A
  Amgen
• A
  AstraZeneca
• G
  GlaxoSmithKline
• AP
  Alexion Pharmaceuticals
• AP
  Alnylam Pharmaceuticals
• IS
  International Society of Nephrology
• B
  BioCryst
• B
  BeiGene
• A
  Argenx
• OC
  Omeros Corporation
• AP
  Astellas Pharma